Univdatos Whatsapp
Radioligand Therapy Market

Global Radioligand Therapy Market is expected to foresee significant growth. APAC to lead the growth!

Global radioligand therapy market is expected to register a CAGR of around 4% over the period of 2021-2027. This is mainly due to the rising incidence of cancer, and it is treated by harnessing the power of radioactive atoms and applying it to advanced cancers through radioligand therapy. Radioligand therapy is able to deliver radiation to target cells anywhere in the body. Major pharmaceutical companies are investing heavily in their products due to the rising prevalence of chronic diseases, awareness of radiotherapy, and the growing geriatric population. According to World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum, and prostate cancers. Furthermore, around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit, and vegetable intake, and lack of physical activity. Therefore, the market for Radioligand Therapy is expected to witness significant growth during the forecast period.

 For a detailed analysis of the Global Radioligand Therapy Market browse through https://univdatos.com/report/radioligand-therapy-market/

Based on product, the market is classified into approved products and potential pipeline. The approved products category accounted for a significant share of the market. This is mainly due to the presence of a wide range of products and the advent of novel and improved methods that are FDA-approved and more effective procedures such as lutetium 177, prostate-specific membrane antigen (PSMA), and other approved products for the treatment of cancer.

Based on indication, the market is categorized into prostate cancer, neuroendocrine tumor (NETs), and others. Among these, prostate cancer is expected to witness the highest CAGR during the forecast period. Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Prostate cancer is treated and managed with a variety of diagnostic and therapeutic items, including radioligand therapy.

For a better understanding of the market adoption of the radioligand therapy industry, the market is analyzed based on its worldwide presence in the countries such as North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Spain, and Rest of Europe); Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), and Rest of World. North America is expected to witness a significant growth rate during the forecast period on account of the growing incidence of cancer and chronic disorders in countries like the U.S. and Canada. The rising clinical research activity and new product launches owing to the presence of well-established market players and frequent product launches in the region. Furthermore, the increased consumer awareness regarding the availability of various radioligand therapy and cancer treatments will drive market growth.

Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=20939

Some of the major players operating in the market include Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc., Bayer AG.

Global Radioligand Therapy Market Segmentation

Market Insight, by Product
• Approved Products
• Potential Pipeline

Market Insight, by Indication
• Prostate Cancer
• Neuroendocrine Tumor (NETs)
• Others

Market Insight, by Biomarker

Market Insight, by Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Rest of World

Top Company Profiles

• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Amneal Pharmaceuticals LLC
• Novartis International AG
• POINT Biopharma Global Inc
• Fusion Pharma
• Clovis Oncology
• Telix Pharmaceuticals
• Lantheus Holdings, Inc.
• Bayer AG.

Leave A Comment

Select Language